Cargando…
Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection
Lantibiotics offer an untapped pipeline for the development of novel antibiotics to treat serious Gram-positive (+) infections including Clostridium difficile. Mutacin 1140 (MU1140) is a lantibiotic produced by Streptococcus mutans and acts via a novel mechanism of action, which may limit the develo...
Autores principales: | Kers, Johan A., Sharp, Robert E., Defusco, Anthony W., Park, Jae H., Xu, Jin, Pulse, Mark E., Weiss, William J., Handfield, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864910/ https://www.ncbi.nlm.nih.gov/pubmed/29615987 http://dx.doi.org/10.3389/fmicb.2018.00415 |
Ejemplares similares
-
OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections
por: Kers, Johan A., et al.
Publicado: (2018) -
The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics
por: Escano, Jerome, et al.
Publicado: (2014) -
Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistant Staphylococcus aureus infection models in mice
por: Ju, Min, et al.
Publicado: (2022) -
Synthesis of a Novel Lantibiotic Using Mutacin II Biosynthesis Apparatus
por: Biswas, Saswati
Publicado: (2023) -
Molecular Recognition
of Lipid II by Lantibiotics:
Synthesis and Conformational Studies of Analogues of Nisin and Mutacin
Rings A and B
por: Dickman, Rachael, et al.
Publicado: (2019)